Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$12.2 million.

  • Rocket Pharmaceuticals' Change in Accured Expenses fell 48621.89% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.6 million, marking a year-over-year decrease of 14090.07%. This contributed to the annual value of $6.1 million for FY2024, which is 4020.89% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Change in Accured Expenses stood at -$12.2 million for Q3 2025, which was down 48621.89% from $8.1 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Change in Accured Expenses peaked at $15.8 million during Q4 2023, and registered a low of -$16.0 million during Q2 2021.
  • Its 5-year average for Change in Accured Expenses is $614578.9, with a median of $2.5 million in 2022.
  • Data for Rocket Pharmaceuticals' Change in Accured Expenses shows a peak YoY increase of 53412.47% (in 2023) and a maximum YoY decrease of 147841.14% (in 2023) over the last 5 years.
  • Rocket Pharmaceuticals' Change in Accured Expenses (Quarter) stood at -$2.0 million in 2021, then soared by 225.19% to $2.5 million in 2022, then skyrocketed by 534.12% to $15.8 million in 2023, then tumbled by 95.09% to $774000.0 in 2024, then crashed by 1682.3% to -$12.2 million in 2025.
  • Its Change in Accured Expenses stands at -$12.2 million for Q3 2025, versus $8.1 million for Q2 2025 and -$5.3 million for Q1 2025.